What Happened?
La Jolla, CA-based Ambrx Appointed Tiecheng Qiao as Chief Executive Officer
Date of management change: June 15, 2015
La Jolla, CA-based Ambrx Appointed Tiecheng Qiao as Chief Executive Officer
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
Tiecheng Qiao is Chief Executive Officer at Ambrx. Previously, Tiecheng held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Harris Kevin, Blair Jeremy, Bolukbasi Kerem, Ronew Sandy, Kelly Brian, Young Robyn, Schalk Lee, Lodge Dan, Olson-Calpe Anne, Tippow Ellen, Valadez Therese
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.